RxDoctor Payments Data

Vaibhav Patel, MD

Cardiology · Columbus, GANPI 1386670073

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $10,833 of the $14,821 with a category attached, or 73.1%. 41 manufacturers reported payments, led by Abbott at 44.9% of the total.

$14,821in general payments, 2019–2025

Across 555 payments — averaging $26.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$7K
  • Pfizer$1K
  • Johnson & Johnson$841
  • Amgen$765
  • Novartis$677
  • AstraZeneca$660
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$3,96027%
  • Food & beverage$10,83373%
  • Education$120%
  • Other$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,821 in reported general payments places this provider in the 85th percentile of 24 cardiology providers in Georgia.

See all cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$326,815
Medicare patients
1,380
Services billed
3,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban664$675,977
EntrestoSacubitril/Valsartan172$207,552
XareltoRivaroxaban124$142,659
FarxigaDapagliflozin Propanediol57$50,246
MultaqDronedarone Hcl20$36,377
Repatha SureclickEvolocumab33$20,326
JardianceEmpagliflozin11$17,550
Ambrisentan14$17,429
Ranolazine ErRanolazine158$15,025
Metoprolol Succinate465$8,131
ClopidogrelClopidogrel Bisulfate302$3,590
Isosorbide Mononitrate ErIsosorbide Mononitrate327$3,165
Atorvastatin Calcium273$2,835
Carvedilol313$2,239
Potassium Chloride105$1,817

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$1,002$675,977664 claims
NovartisEntresto$677$207,552172 claims
Johnson & JohnsonXarelto$841$142,659124 claims
AstraZenecaFarxiga$660$50,24657 claims
Sanofi-aventis U.S. LLCMultaq$107$36,37720 claims
Boehringer IngelheimJardiance$228$17,55011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 24 cardiology providers in Georgia.

Other cardiology in Columbus

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →